octreotide acetate / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 141 Diseases   27 Trials   27 Trials   1501 News 


«1234567891011»
  • ||||||||||  metformin / Generic mfg., everolimus / Generic mfg., octreotide acetate / Generic mfg.
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  MetNET1: Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs (clinicaltrials.gov) -  Jun 9, 2021   
    P2,  N=43, Recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Jun 2017 --> Jun 2021 | Trial primary completion date: Jun 2017 --> Jun 2021
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    Clinical, Journal:  Long-acting Release Octreotide for Pediatric Upper Gastrointestinal Bleeding. (Pubmed Central) -  May 26, 2021   
    Conclusions Lenvatinib with octreotide LAR combination is an effective and well-tolerated regimen as second-line treatment in patients with advanced G1-2 extra-pancreatic NETs. We consider that this report could help in the management of similar pediatric patients with UGIB due to PHT without conventional therapeutic possibilities.
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    Clinical, Journal:  Therapeutic effect of presurgical treatment with longacting octreotide (Sandostatin® LAR®) in patients with acromegaly. (Pubmed Central) -  May 25, 2021   
    We consider that this report could help in the management of similar pediatric patients with UGIB due to PHT without conventional therapeutic possibilities. We have shown good surgical outcome in patients with acromegaly after pre-treatment with somatostatin analogue, and good tolerance and safety of the therapy, supporting the national recommendation for pre-surgical treatment with long-acting somatostatin analogues in acromegaly patients.
  • ||||||||||  Avastin (bevacizumab) / Roche, Sandostatin LAR Depot (octreotide acetate) / Novartis
    Review, Journal, Combination therapy:  Octreotide long-acting release (LAR) in combination with other therapies for treatment of neuroendocrine neoplasia: a systematic review. (Pubmed Central) -  May 21, 2021   
    The review summarizes the effectiveness and available safety data on octreotide LAR in combination with other therapies in patients with NEN and may provide suggestions to address the therapeutic strategy. Further comparative head-to-head studies are needed to understand which is the best combination treatment for patients with progressive NEN after failure of first-line therapy.
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    Journal:  Trimethoprim-sulfamethoxazole-induced refractory hypoglycaemia successfully treated with octreotide. (Pubmed Central) -  May 15, 2021   
    We reviewed previous case reports described in the literature of TMP-SMX-induced hypoglycaemia, in which renal insufficiency was noted to be a common predisposing risk factor in an overwhelming majority of cases. In refractory cases of TMP-SMX-induced hypoglycaemia, intravenous octeotride may be considered for treatment.
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    Biomarker, Trial completion, Tumor cell:  Circulating Tumor Cells and Tumor DNA in HCC and NET (clinicaltrials.gov) -  Apr 28, 2021   
    P=N/A,  N=167, Completed, 
    This randomized, blinded study evaluating pt comfort with SSAs found minimal pain with both agents and no significant differences in pain scores between octreotide LAR versus lanreotide. Recruiting --> Completed
  • ||||||||||  Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
    Enrollment closed, Trial completion date, Trial primary completion date, Metastases:  A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide (clinicaltrials.gov) -  Apr 21, 2021   
    P4,  N=53, Active, not recruiting, 
    No new safety signals emerged during the median 6.3 year long-term follow-up. Recruiting --> Active, not recruiting | Trial completion date: Sep 2021 --> Sep 2023 | Trial primary completion date: Sep 2021 --> Sep 2023
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    Clinical, Journal:  Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with Lu-DOTATATE. (Pubmed Central) -  Mar 28, 2021   
    A positive repeated measures correlation was found between diary-recorded symptom scores and questionnaire-recorded pain, diarrhea, and flushing. In addition to efficacy and quality of life benefits, symptom diaries from NETTER-1 demonstrated that treatment with Lu DOTATATE was associated with statistically significant reductions in abdominal pain, diarrhea, and flushing, constituting the core symptoms of patients with progressive midgut NETs, compared with high-dose octreotide LAR, supporting a beneficial effect of Lu DOTATATE on HRQoL.
  • ||||||||||  Leukine (sargramostim) / Partner Therap, SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
    Trial completion date, Trial primary completion date, Metastases:  Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors (clinicaltrials.gov) -  Mar 5, 2021   
    P1,  N=10, Recruiting, 
    Active, not recruiting --> Completed Trial completion date: Jan 2022 --> Jun 2023 | Trial primary completion date: Jan 2021 --> Jun 2022
  • ||||||||||  bromocriptine / Generic mfg.
    [VIRTUAL] DO WE NEED A PITUITARY DISEASES REGISTRY IN LATVIA? () -  Feb 24, 2021 - Abstract #ICE2021ICE_474;    
    Based on the study of the pituitary disease registry in Latvia, a unified database of pituitary diseases pts has been created. A state founded registry may be set up in the future.
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    [VIRTUAL] THERAPEUTIC CHALLENGES IN A PATIENT WITH AN UNUSUAL AND SEVERE CASE OF MCCUNE-ALBRIGHT SYNDROME AND POLYSOTOTIC FIBROUS DYSPLASIA. () -  Feb 24, 2021 - Abstract #ICE2021ICE_356;    
    From the age of 11 through 18 years old, he received treatment with Cabergoline, Pamidronate EV every 6 months, Cholecalciferol, Calcium and Calcitriol...Octreotide LAR 30 mg every 28 days, Zoledronic acid 5 mg/month, Cabergoline 3 mg/week, Cholecalciferol and calcium were indicated...Clinical The degree of severity, unusual presentation and the low incidence of MAS / DF motivated the communication of this case. Treatment was aimed at optimizing life quality and minimizing the morbidity associated with bone deformities, fractures and compromise of vital structures.
  • ||||||||||  Somavert (pegvisomant) / Pfizer, Sandostatin LAR Depot (octreotide acetate) / Novartis
    Clinical, Journal, HEOR:  Cost-effectiveness and efficacy of a novel combination regimen in acromegaly: a prospective, randomized trial. (Pubmed Central) -  Feb 24, 2021   
    Treatment was aimed at optimizing life quality and minimizing the morbidity associated with bone deformities, fractures and compromise of vital structures. Low-dose SRL plus weekly pegvisomant represents a novel dosing option for achieving cost-effective, optimal biochemical control in patients with uncontrolled acromegaly requiring combination therapy.
  • ||||||||||  temozolomide / Generic mfg., capecitabine / Generic mfg.
    Clinical, Journal:  Capecitabine and temozolomide in patients with advanced pulmonary carcinoid tumours. (Pubmed Central) -  Feb 16, 2021   
    Conclusions CAPTEM induced a modest response and PFS rate, comparable to other studies with temozolomide in patients with advanced PC. The efficacy of CAPTEM should be compared to that of monotherapy with temozolomide in a prospective clinical trial.
  • ||||||||||  Somavert (pegvisomant) / Pfizer, Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
    [VIRTUAL] Clinical Presentation and Management of Patients With Acromegaly at a University Hospital (On-Demand) -  Feb 2, 2021 - Abstract #ENDO2021ENDO_1560;    
    Twelve patients were subsequently excluded from this analysis - nine patients who had been recently diagnosed and were awaiting surgical treatment as well as three patients who had been lost to follow-up. The study sample (n=60) included forty females patients (67%).
  • ||||||||||  bromocriptine / Generic mfg.
    [VIRTUAL] Pituitary Diseases Registry Study in Latvia. Part 1. (On-Demand) -  Feb 2, 2021 - Abstract #ENDO2021ENDO_1550;    
    A state register may be set up in the future. Unless otherwise noted, all poster abstracts presented at ENDO 2021 are embargoed until 11 AM Eastern on Saturday, March 20.
  • ||||||||||  dexamethasone / Generic mfg.
    [VIRTUAL] Antipsychotic Medication Use Delays Diagnosis of Acromegaly (On-Demand) -  Feb 2, 2021 - Abstract #ENDO2021ENDO_1453;    
    Unless otherwise noted, all poster abstracts presented at ENDO 2021 are embargoed until 11 AM Eastern on Saturday, March 20. For oral presentations, the abstracts are embargoed until the session begins.
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    [VIRTUAL] Role of Octreotide in Sulfonylurea-Induced Hypoglycemia (On-Demand) -  Feb 2, 2021 - Abstract #ENDO2021ENDO_1127;    
    Glucose, on the other hand, would stimulate insulin release and cause rebound hypoglycemia. Boyle et al, showed that octreotide was superior to diazoxide and glucose in preventing sulfonylurea-induced hypoglycemia.
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    [VIRTUAL] A Curious Case of Hypoglycemia: A Rare Occurrence of Insulin Autoimmune Syndrome (On-Demand) -  Feb 2, 2021 - Abstract #ENDO2021ENDO_1081;    
    Home medications were carvedilol and simvastatin...For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO 2021.
  • ||||||||||  Leukine (sargramostim) / Partner Therap, SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
    Trial completion date, Metastases:  Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors (clinicaltrials.gov) -  Jan 6, 2021   
    P1,  N=10, Recruiting, 
    Clinical and laboratory aspects relevant to this entity are reviewed, emphasizing the usefulness of octreotide in the management of the reported case. Trial completion date: Dec 2020 --> Jan 2022